Page Title
Clinical Trial Finder
Observational Closed to Enrollment
An Ocular Safety Study of Kalyedeco-Treated Children 11 Years of Age or Younger with CF (Vertex VX-770-115)
This trial is designed to evaluate the risk of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of children with Cystic Fibrosis who are 11 years of age or younger at the time of ivacaftor (Kalydeco) treatment initiation and are receiving or planning to receive commercially-available ivacaftor (Kalydeco) in the US.
Eligibility
-
Age:
6 Years to 11 Years -
Mutation(s):
One Copy F508del or No Copies F508del -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Study Design
-
Study Type: ?more info
Observational -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
2 years -
Number of Study Visits:
5
Additional Information
-
Phase: ?more info
Phase Four/Post-Approval -
Study Sponsor: ?more info
Vertex -
Study Drugs:
N/A
Study Sites
-
Closed to Enrollment
Alabama
The Children's Hospital Alabama, University of Alabama at Birmingham, Birmingham, AL 35233
-
Closed to Enrollment
Arizona
Tucson Cystic Fibrosis Center, Tucson, AZ 85724
-
Closed to Enrollment
California
Miller Children's and Women's Hospital Long Beach, Long Beach, CA 90806
-
Closed to Enrollment
Colorado
Children's Hospital Colorado, Aurora, CO 80045
-
Closed to Enrollment
Delaware
Alfred I. duPont Hospital for Children, Wilmington, DE 19803
-
Closed to Enrollment
Florida
All Children's Hospital, St. Petersburg, FL 33701
-
Closed to Enrollment
Florida
University of Florida, Gainesville, FL 32610
-
Closed to Enrollment
Idaho
Saint Luke's Cystic Fibrosis Center of Idaho, Boise, ID 83702
-
Closed to Enrollment
Illinois
Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611
-
Closed to Enrollment
Indiana
Riley Hospital for Children, Indianapolis, IN 46202
-
Closed to Enrollment
Kentucky
University of Louisville, Louisville, KY 40202
-
Closed to Enrollment
Maine
Maine Medical Partners Pediatric Specialty Care, Portland, ME 04102
-
Closed to Enrollment
Massachusetts
Boston Children's Hospital, Boston, MA 02115
-
Closed to Enrollment
Michigan
Children's Hospital of Michigan, Detroit, MI 48201
-
Closed to Enrollment
Minnesota
The Minnesota Cystic Fibrosis Center, Minneapolis, MN 55454
-
Closed to Enrollment
Missouri
Children's Mercy Kansas City, Kansas City, MO 64108
-
Closed to Enrollment
Nebraska
University of Nebraska Medical Center, Omaha, NE 68114
-
Closed to Enrollment
New York
University of Rochester Medical Center Strong Memorial, Rochester, NY 14642
-
Closed to Enrollment
Ohio
Children's Hospital Medical Center of Akron, Akron, OH 44308
-
Closed to Enrollment
Ohio
Toledo Children's Hospital, Toledo, OH 43606
-
Closed to Enrollment
Ohio
Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229
-
Closed to Enrollment
Oklahoma
Oklahoma Cystic Fibrosis Center, OKC, OK 73104
-
Closed to Enrollment
Oregon
Oregon Health & Science University, Portland, OR 97239
-
Closed to Enrollment
Pennsylvania
Children's Hospital of Philadelphia, Philadelphia, PA 19104
-
Closed to Enrollment
Pennsylvania
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224
-
Closed to Enrollment
Tennessee
East Tennessee Children's Hospital, Knoxville, TN 37916
-
Closed to Enrollment
Tennessee
Vanderbilt Children's Hospital, Nashville, TN 37232
-
Closed to Enrollment
Texas
Cook Children's Medical Center, Fort Worth, TX 76104
-
Closed to Enrollment
Utah
Primary Children's Cystic Fibrosis Center, Salt Lake City, UT 84113
-
Closed to Enrollment
Virginia
University of Virginia, Charlottesville, VA 22903
-
Closed to Enrollment
Washington
Providence Medical Group, Cystic Fibrosis Clinic, Spokane, WA 99204
-
Closed to Enrollment
West Virginia
West Virginia University - Morgantown, Morgantown, WV 26507
Eligibility
-
Age:
6 Years to 11 Years -
Mutation(s):
One Copy F508del or No Copies F508del -
FEV1% Predicted:
No FEV1 Limit
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More